欢迎来到 CSNpharm! 产品仅用于科研!
首页 Compound Arrays 促销产品
400-920-2911 sales@csnpharm.cn    

c-Met/HGFR

c-Met/HGFR

货号 产品名 CAS号 信息
CSN17399 Tyrosine Kinase Inhibitor 1021950-26-4 Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma.
CSN12917 Tivantinib 905854-02-6 Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM with little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.
CSN12733 SU11274 658084-23-2 SU11274 is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR or Tie2.
CSN25214 SCR-1481B1 x(NH2(OH)3) N/A SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
CSN19153 S49076 1265965-22-7 S49076 is a potent inhibitor of MET, AXL/MER, and FGFRs.
CSN23572 Norcantharidin 29745-04-8 Norcantharidin is a potential antitumor agent.
CSN23685 Ningetinib Tosylate 1394820-77-9 Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively.
CSN17658 MK-8033 HCl 1283000-43-0 MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN13613 MK-8033 1001917-37-8 MK-8033 is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN17560 LY2801653 2HCl 1206801-37-7 LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase (Ki= 2 nM).
CSN22436 JNJ-38877618 943540-74-7 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
CSN19988 Herbacetin 527-95-7 Herbacetin, a natural product isolated and purified from the herbs of Equisetum hyemale L. It was found to efficiently block the enzymatic activity of SARS-CoV 3CLpro.
CSN17479 Glesatinib HCl 1123838-51-6 Glesatinib HCl is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
CSN24316 Dihexa acetate 2453297-24-8 Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.
CSN25585 RON-IN-1 913376-84-8 c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner.
CSN22378 c-Met-IN-2 1635406-73-3 c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.
CSN23729 PLB-1001 1440964-89-5 Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
CSN25296 BAY 474 1033767-86-0 BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
CSN17199 AMG-458 913376-83-7 AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
CSN16259 Altiratinib 1345847-93-9 Altiratinib is a c-MET/TIE-2/VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
<< PREV 1 2 NEXT >>